Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products
SistemPSCCheck™ is a first-in-class miRNA-based assay, for high sensitivity assessment of residual undifferentiated PSCs in derived cell preparations. SistemPSCCheck™ is a service product safety and batch release assay to support the clinical and commercial development of pluripotent stem cell-derived cell therapy products.
Sistemic Ltd. is excited to announce that they will be attending 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to give an overview of SistemPSCCheck™ and to discuss the assay with representatives of Cell therapy companies, regulators and thought-leaders working in the field of pluripotent stem cell-derived cell therapy products.
Jim Reid, CEO stated "This is a critical milestone for the company representing the first productization of our broad IP portfolio and the first in our planned range of SistemCheck™ products which will all be designed to help the Cell and Gene Therapy industry develop safe and robust products. The iPSC field holds great promise, but without products like SistemPSCCheck™, the necessary controls over manufacturability will not enable the sector to provide the undoubted revolutionary treatments that are possible. On the back of our recent successful funding round, Sistemic is perfectly set for rapid growth in 2018.”
David Mallinson, VP of Scientific Operations added "We are delighted to be able to attend the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells to give an overview of the development of the SistemPSCCheck™ to representatives of Cell Therapy companies, regulators and thought-leaders working with pluripotent stem cell-derived cell therapy products. SistemPSCCheck™ is a first-in-class service product and will facilitate the clinical and commercial progress of pluripotent stem cell-derived cell therapy products, allowing them to be developed to safer clinical products more quickly"
Potential partners interested in receiving further information on the availability of the test or to be part of an Early Access Programme should contact email@example.com
Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell and Gene Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. Furthermore, cell products in the later stages of clinical development benefit from SistemQC™ miRNA-based profiling approach in facilitating patient stratification and monitoring the response to the treatment. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™. Sistemic has a worldwide customer base and a strong intellectual property portfolio.
For more information contact: firstname.lastname@example.org